https://www.sciencedaily.com/releases/2020/09/200909140314.htm

The findings are reported today, Sept. 9, in Science

In the experiments, the lead antiviral candidate, named LCB1, rivaled the best-known SARS-CoV-2 neutralizing antibodies in its protective actions. LCB1 is currently being evaluated in rodents.